Our vision is to develop pharmaceuticals that contribute to normalized lives for patients

New class of drugs for treatment of severe inflammatory conditions and resistant cancer

The fractalkine axis controls pro-inflammatory cells and cancer cells with precision

Our business

Kancera develops pharmaceuticals for life threatening diseases with high medical needs

Read More

Our science

Kancera develops a new class of drugs targeting the fractalkine axis

Read More

Our pipeline

Kancera’s two fractalkine blocking drug candidates are currently being studied in three ongoing clinical trials

Read More

CEO statement

“Kancera is a world leading pioneer in the field of small molecule CX3CR1 antagonists. This is now manifested with our candidate drugs rugocrixan and fosrugocrixan setting the name standard for this new class of drugs.”

Peter Selin, CEO Kancera

Press Releases

Events

Presentations

Presentation of Kancera’s 2025 Q2 Interim Report (in Swedish)